Why infusion centers are HRSA’s next compliance minefield
When HRSA auditors arrived at a hospital in Ohio last spring, they didn’t start in the retail contract pharmacy or the mixed-use unit. They went straight to the outpatient infusion center. That wasn’t random. HRSA’s 2025 audit plan flags infusion sites as a “high variance point-of-care,” where 340B-eligible drug usage and charge capture often don’t align. The audit team wasn’t just checking patient eligibility, they were tracing individual vials of paclitaxel and infliximab back through infusion logs and GPO purchase histories. One mismatched vial, documented in the EMR under a Medicare Part B claim but sourced from the 340B accumulator, turned what looked like one compliance issue into five.
I’ve seen that same pattern during three separate onsite audits since 2023. Infusion centers sit right where complex ordering, multi-dose vials, and mixed payer populations collide. Nurses draw from a single vial for two patients, techs record partial waste, and stretched pharmacy teams try to tag every transaction inside the split-billing system. HRSA knows diversion hides here; matching each draw to an eligible patient is harder than any outpatient fill. So, a 340B inventory reconciliation guide can’t just rehash eligibility rules. It needs operational controls that make diversion statistically near impossible. Otherwise, you’re building on sand.
Rebuilding inventory logic around provider order data, not charges
Too many infusion centers still reconcile by matching purchases to billing charges. That’s backward. HRSA’s 2012 program notice is explicit: 340B eligibility ties to the provider encounter and the covered entity relationship, not to payer status or charge code. When HRSA or Apexus auditors ask for documentation, they expect a traceable chain, provider order, administration record, and purchasing proof all linked. If your split-bill system relies mainly on charge codes or cost centers instead of order-level data, you’re already working in a different language than HRSA.
I’ve rebuilt workflows that used HCPCS triggers for 340B accumulation and uncovered claims tied to ineligible providers. The fix wasn’t pretty but it worked: reconciliation had to start before a single vial hit the ADC or floor stock. Pharmacy verification of an eligible encounter first. Every prescriber and location matched to the HRSA-registered child site list weekly, because quarterly checks are performative at best. When a 340B vial ends up in a non-registered department, the only defense HRSA accepts is contemporaneous proof that the encounter met the covered entity test. “We fixed it later” won’t cut it. Never has.
For systems built in Epic or Cerner, your integration point sits inside the medication administration record. Tie your reconciliation timestamp to that event, not to the charge post date. That’s what auditors trace in HRSA’s 340B Compliance Assessment File requests, the link between administered dose and purchase lot number. Feed it backward from billing, and transparency disappears.
The gap between HRSA’s expectations and actual infusion practice
Nothing triggers HRSA findings faster than shared vials. Technically, HRSA allows multi-patient use if each patient meets eligibility and the accounting precisely attributes drug usage. Realistically, it’s defensible only if you track lots per patient. In one audit response from a Midwest DSH hospital, HRSA rejected nearly half of their infliximab doses because wastage lines weren’t tied to specific administrations. The letter spelled it out: the covered entity “could not demonstrate that shared vial allocations were accurately tracked per eligible patient.”
Total volume in versus out won’t satisfy auditors. HRSA expects evidence at the patient level. Two patients, same day, same lot? You need two administration records and one traceable lot number in your purchase file. Miss that, and the dose fails the diversion test. That’s why higher-performing programs now use barcode verification at the admixture hood, linking each NDC scan to the encounter ID. It’s survival, not overkill, when HRSA walks in the door.
Waste lines create the same trap. Medicare pays for correctly reported waste, but HRSA still treats it as a usage event under covered entity rules. If the wasted amount sits on a non-340B accumulator, you’ve split the vial’s compliance path. Run waste reports monthly and force your split-bill system to record each waste line as distinct usage. HRSA has accepted that method when the covered entity can prove waste isn’t double-counted across accumulators. Look, that’s as fair as it gets in this terrain.
Preparing for HRSA’s 2025 reconciliation audits
HRSA’s FY2025 audit plan, quietly previewed through an OPAIS contractor RFP last December, introduces three infusion-specific tests: direct purchase-lot validation for infused drugs over $5,000 per dose, time-driven eligibility sampling based on administration date, and wastage reconciliation down to the NDC-lot level. That’s where the scrutiny is going. Entities still reconciling by monthly summaries instead of transaction-level detail are heading for trouble.
A working 2025 infusion reconciliation guide should document four items: the patient encounter record proving eligibility under HRSA Notice 2015-1; the provider registration and cost center mapping that confirm a HRSA-listed site; the purchase invoice with the sourced lot and NDC; and the administration or waste record linking back to that same lot. Miss any one, and you’ve created the root of a diversion or duplicate discount. HRSA hasn’t stated whether it’ll extend this model to oncology-only centers, but given OIG’s recent Medicare Part B reviews, it’s just a matter of time.
Infusion reconciliation has outgrown its accounting roots. It’s now where HRSA will define how “patient of the covered entity” applies in mixed-use spaces. The 2022 Genesis Health System ADR case, still awaiting appeal, shows HRSA’s willingness to push hard on infusion data that don’t line up with OPAIS registration. Fourteen disputed vials led to a $1.4 million repayment. That’s the new landscape.
If you’re still doing monthly spreadsheet tie-outs, the clock is already ticking. HRSA expects near-real-time auditability: drug in, administration captured, accumulator updated, reconciliation available inside 48 hours. Anything slower leaves too much room for diversion and not enough proof when HRSA calls. Build your process like they’re walking in tomorrow, because soon enough, they will.